⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

Official Title: Protect Neuro - Prospective Cohort Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

Study ID: NCT02993276

Conditions

Neuroma

Interventions

Neurocap®

Study Description

Brief Summary: PROSPECTIVE COHORT EVALUATION OF NEUROCAP® In the Treatment of symptomatic Neuroma (PROTECT Neuro) This post-market surveillance study is conducted to provide post market surveillance information regarding long-term performance and ease of use of the Polyganics nerve capping device (NEUROCAP®) for reduction of the development of peripheral symptomatic end-neuroma.

Detailed Description: 1. Device description NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma. NEUROCAP® is composed of the same biocompatible, bioresorbable copolyester composing the NEUROLAC® nerve guide, Poly(68/32\[15/85 D/L\] Lactide-Ԑ-Caprolactone) (PLCL). 2. Objective This post-market surveillance study is conducted to provide post market surveillance information regarding long-term performance and ease of use of the Polyganics nerve capping device (NEUROCAP®) for reduction of the development of peripheral symptomatic end-neuroma. 3. Study design This post-market surveillance study consists of a cohort study to provide post market surveillance information regarding long-term performance and ease of use of the NEUROCAP® for reduction of the development of peripheral symptomatic end-neuroma in the upper and lower extremity. Sub analyses will be performed regarding demographics and medical background.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Arizona Center for Hand Surgery, Phoenix, Arizona, United States

Stanford Medical Center Hand and Upper Limb Center, Redwood City, California, United States

Buncke Clinic, San Francisco, California, United States

Veterans affairs Medical Center Portland, Portland, Oregon, United States

Geisinger Clinic, Danville, Pennsylvania, United States

University of Pennsylvania, Philadelphia, Pennsylvania, United States

The Philadelphia Hand Center (affiliated to Thomas Jefferson Hospital), Philadelphia, Pennsylvania, United States

Virginia Commonwealth University Medical Center, Richmond, Virginia, United States

Clinique Chirurgicale Victor Hugo Paris, Paris, , France

BG Trauma Center Frankfurt am Main GmbH, Frankfurt am Main, , Germany

Ospedale San Guiseppe Milano, Milano, , Italy

Parc Sanitari Sant Joan de Deu, Barcelona, , Spain

Sahlgrenska University Hospital Gothenburg, Goteborg, , Sweden

University Hospital Linköping, Linkoping, , Sweden

University Hospital Lund - Department of Hand Surgery, Malmo, , Sweden

Birmingham Hand Centre, Birmingham, , United Kingdom

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: